Globe Life Inc (GL)
Official siteFINANCIAL SERVICES • INSURANCE - LIFE • NYSE
Market Cap: $12.13B
Last updated: Nov 17, 2026 at 11:06 AM ET
Globe Life Inc (GL) Stock Forecast
Analysts expect Globe Life (GL) to earn $15.49 per share in the fiscal year ending Dec 31, 2026, on revenue of $6.39B. Of 11 analysts, 7 rate the stock Buy or Strong Buy, 4 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 11 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 11 ratings average 2.09, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 64% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 3 | 27.3% |
| Buy | 4 | 36.4% |
| Hold | 4 | 36.4% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 11
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 5.7% and revenue estimates rise 6.1%.
- Fiscal year ending Dec 31, 2026
- $15.49
- EPS consensus, revenue $6.39B
- Fiscal year ending Dec 31, 2027
- $16.38
- EPS consensus, revenue $6.78B
- Next report
- Feb 2, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $15.49 | $15.41 to $15.57 | 11 | $6.39B | $6.38B to $6.39B | 3 |
| Dec 31, 2027 | $16.38 | $16.11 to $16.56 | 11 | $6.78B | $6.73B to $6.81B | 3 |
Quarterly Estimates
The EPS consensus rises from $3.73 for the quarter ending Dec 31, 2026 to $3.78 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $3.73 | $3.47 to $3.86 | 17 | $1.60B | $1.30B to $1.71B | 7 |
| Mar 31, 2027 | $3.78 | $3.65 to $4.01 | 10 | $1.67B | $1.67B to $1.67B | 1 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 3 upward and 26 downward EPS revisions. Cuts outnumber raises in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 11 |
| Fiscal year ending Dec 31, 2027 | 3 | 7 |
| Quarter ending Mar 31, 2027 | 0 | 8 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has fallen 1.5% from $15.72.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $15.49 | $15.72 | $15.73 | $15.73 | $15.72 | -1.5% |
| Fiscal year ending Dec 31, 2027 | $16.38 | $16.51 | $16.50 | $16.50 | $16.50 | -0.8% |
| Quarter ending Mar 31, 2027 | $3.78 | $3.87 | $3.90 | $3.90 | $3.90 | -3.2% |
Frequently Asked Questions About GL
What is the GL stock forecast?
Consensus analyst estimates put Globe Life's EPS at $15.49 for the fiscal year ending Dec 31, 2026, on revenue of $6.39B. The consensus rating from 11 analysts is Buy.
How do analysts rate GL stock?
Of 11 analysts covering Globe Life, 3 rate it Strong Buy, 4 Buy, 4 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from GL next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $15.49, with estimates from $15.41 to $15.57 from 11 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $16.38, with estimates from $16.11 to $16.56 from 11 analysts.
What revenue do analysts expect from Globe Life next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $6.39B, with estimates from $6.38B to $6.39B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $6.78B, with estimates from $6.73B to $6.81B.
How many analysts cover GL?
11 analysts rate Globe Life stock, and 11 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
GL pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors